The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|August 5, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 5, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of August 3, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 32%
• Aged ≥65 years 39.1%
Fully vaccinated plus 1 booster dose:
• Total US population 48.2%
Fully vaccinated in key age groups:
• Total US population 67.2%
• Aged ≥5 years 71.4%
• Aged ≥65 years 91.8%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of August 5, 2022 at 3:20 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 510 857
• Texas 337 289
• Florida 298 317
• Total US confirmed cases 92 049 015
• Total US confirmed deaths 1 033 132
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 582 587 747
• Deaths 6 414 368 • Vaccine doses administered 11 998 884 824
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement